Novartis Therapy Seen as Cost-Effective at Up to $1.5 Million
Comment of the Day

February 25 2019

Commentary by Eoin Treacy

Novartis Therapy Seen as Cost-Effective at Up to $1.5 Million

This article by James Paton for Bloomberg may be of interest to subscribers. Here is a section:

The experimental treatment, which could be launched in the first half of 2019, would be an alternative to Biogen Inc.’s Spinraza, a treatment given in regular doses that patients must take for the rest of their lives. Spinraza costs $750,000 in the U.S. for the first year and $375,000 a year thereafter.

Switzerland-based Novartis is now wrestling with the question of how to price a potential cure. As a number of drugmakers advance into gene therapy in a bid to fix potentially lethal DNA flaws, governments, insurers and other payers are trying to figure out how to pay for the revolutionary treatments meant to be given to patients a single time.

Eoin Treacy's view

Genetic sequencing, editing and synthetic biology represent some of the most profound innovations for the healthcare sector in generations because they hold out the increasingly likely possibility of delivering cures. That’s terrible news for the conventional pharmaceutical industry which has historically depended on treating the symptoms of chronic conditions.

Click HERE to subscribe to Fuller Treacy Money Back to top